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The Hanover Consensus Group (HCG) has put
forward their recommendations for conducting eco-
nomic evaluations [1]. It is a remarkable achievement
to bring together most of the health economics com-
munity in Germany. To reach consensus in such a large
group, however, much must be left unspeciﬁed and the
exercise tends to be a search for the lowest common
denominator.
As strongly suggested by the HCG, the perspective,
the selection of instruments, as well as the normative
requirements for health economic evaluation depend
on the decision-maker. It is surprising therefore that
the authors of a report purporting to be “German
recommendations” did not consider the German
decision-making context based on the New Health Act
nor the way the German Federal Joint Committee
(G-BA) will give assignments to the Institute for
Quality and Efﬁciency in Health Care (Institut für
Qualität und Wirtschaftlichkeit im Gesundheitswesen,
IQWiG).
The legal requirements for assessments of the rela-
tion of costs to beneﬁts of health technologies are
embedded in the recent German legislation (Social
Code Book V § 35b). The speciﬁc constraints they
impose for the German context are carefully taken into
account in the forthcoming Methods for Economic
Evaluations for the German Statutory Health Care
System produced by an International Committee of
Experts on behalf of IQWiG. There, interested parties
will ﬁnd explicit, precise recommendations for each
step of an economic evaluation intended to inform
German decision-makers.
Although the HCG states that the consensus “repre-
sents a rational approach for a structured resource
allocation” and a “ ‘construction kit’ to standardize
. . . applied methods,” they provide very little actual
guidance on what ought to be done, limiting themselves
instead to various lists of options—few speciﬁc to
Germany—and the exhortation that the analyst justify
the choice. They claim “to represent the framework
for conducting health economic evaluation studies in
Germany” but do not make the approach concrete,
particularly in terms of bridging the gap between health
economics and evidence-based medicine.
It is undoubtedly difﬁcult in such a short space to
specify methods fully but many pronouncements are
made with no indication as to how the lofty goals are to
be met, not even references to where the reader might
ﬁnd the details. For example, HCG states that “Dis-
tributive and ethical problems and issues can be incor-
porated in the study if this is required” but leave the
reader mystiﬁed as to how this very difﬁcult aspect is to
be accomplished. They suggest that if clinical studies
have low external validity, they “. . . should be supple-
mented by high-quality health economic studies with
greater external validity” but it remains unclear what
speciﬁc methodological recommendation the HCG is
making in this regard and they give no cluewhat criteria
should be taken into account when making these judg-
ments in practice. They propose that the analysis “may
compare the approach in question with the most fre-
quent, the clinically most effective or the most efﬁcient
alternative” but do not indicate which is to be preferred
or why, much less how those rankings are to be estab-
lished in the ﬁrst place. We are told that “existing
inefﬁciencies in the system and their cost effects also
should be listed and discussed separately” with no hint
of what these are, how they should be identiﬁed, or
what is meant by their cost effects.
Even when the guideline is concrete, many puzzling
aspects remain. The HCG states that “priority should
be given to the societal perspective” without justifying
this for the German context or explaining how it is to
be done. Truly after this demand would make it nec-
essary to assess all consequences of an intervention not
only throughout the health care system (including for
teaching, research, employment, and so on) but also
stretching beyond into other parts of the economy.
This is obviously not a practical task and it is unclear
to which actual decision-makers such a perspective
would apply. It is said that “A marginal analysis
should be performed to quantify the costs and out-
comes of an additionally produced unit” but the
grounds for doing this in Germany are not
stipulated—particularly when it is also stated that
“market procurement prices” should be used—“unit”
is undeﬁned as is what it means to “produce” one, and
the baseline from which the margin is measured is not
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given. The analyst is told to provide “the derivation
of the hypotheses,” a seemingly stray clinical trial idea
that bears little relevance to the quantiﬁcation at issue
in economic evaluations. Suggestions for sensitivity
analyzes are very permissive, with probabilistic ana-
lyzes to be done “if possible,” with no indication how
the possibility should be assessed, or why it would not
always be possible.
The HCG states that clinical studies evaluating
medical efﬁcacy are an indispensable prerequisite for
economic evaluation—an important aspect that is
part of IQWiG’s evaluation methods. For effectiveness,
HCG also “requires studies that have a scientiﬁc
design comparable to the designs in randomized, con-
trolled studies” but cites no sources for such method-
ology; and then, they go on to allow expert opinion
with the simple proviso that “the selection criteria of
the panel and the process of forming consensus must
be disclosed and described in detail.” How such a
disclosure would render expert opinion of comparable
validity to randomized studies remains a mystery.
The HCG favors determining “what beneﬁt the
used resources would have achieved in the next best
alternative.” We are not told how his theoretically
correct approach is to be implemented, and it fails to
meet the basic requirements of the German decision-
making authorities. This approach would be useless in
Germany today as the decision-makers do not have the
mandate to perform such comparisons.
Little seems to have been changed from the previous
HCG version published almost a decade ago. Meeting
the worthy goals of the HCG—to provide standards
and yet promote methodological progress and scientiﬁc
innovation in health economics—requires more than a
compilation of disparate current approaches. Actual
“recommendations” must be concrete, tailored to the
German context, coherent, and carefully justiﬁed, if
they are to be helpful to German decision-makers.
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